Galapagos enters into global alliance with Janssen Pharmaceutica on rheumatoid arthritis research
Multi-target alliance to discover, develop, and commercialize oral small molecule therapeutics for rheumatoid arthritis
With the signing of the agreement, Janssen will make an initial up-front cash payment of EUR 15 million to Galapagos. In addition, Janssen will make a EUR 2 million milestone payment for the selection of GT146, one of Galapagos' advanced RA programs, into the alliance. Under the alliance agreement, Galapagos will be responsible for the discovery of small molecule product candidates for those novel, validated RA targets that are chosen by Janssen. Galapagos will develop product candidates through to Phase IIa Proof of Concept (POC) clinical trials. During the term of the collaboration, Galapagos is eligible to receive success-based progress milestones from Janssen. Upon Galapagos' achievement of POC for a product candidate, Janssen has an exclusive option to license the product candidate from each alliance program and will then assume full responsibility for further clinical development and worldwide commercialization, at its expense. For each alliance program licensed by Janssen, contingent on discovery, development and regulatory accomplishments, Galapagos could receive option exercise fees and milestone payments up to EUR 73 million, plus royalties on net sales of each approved new RA drug.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.